The Covid-19 Vaccine


  • Dr. Arvind Vyankatesh Athavale Professor and Head, Department of Community Medicine, Chirayu Medical College & Hospital, Bhopal, Madhya Pradesh, India.


COVID-19 Vaccine, Herd Immunity, Vaccine Hesitancy


To achieve the required level of herd immunity against SARS CoV-2, widespread deployment of COVID-19 vaccine is the best intervention to safeguard against the high mortality, economic disruption, and the major adjustments to our way of life. Vaccine development and its roll out in the market typically goes through various phases viz. the exploratory phase, the preclinical study, human clinical trials, review and approval, manufacturing, and post-marketing surveillance. There are various COVID-19 vaccine platforms broadly classified as gene-based vaccines and the proteinbased vaccines. As per WHO the efficacy of 50% is sufficient for a vaccine whereas an efficacy of less than 60% may fail to achieve herd immunity. Several international organizations are working in collaboration to ensure sufficient financing and fair distribution of the vaccine supply throughout the world. In India there are two vaccines which have been rolled out for public use viz. Covishield vaccine developed by Astra Zeneca in collaboration with Oxford University, UK and manufactured by the Serum Institute of India; and the Covaxin manufactured by the Bharat Biotech a local manufacturing company in collaboration with the Indian Institute of Medical Research (ICMR), India. Currently there are
242 candidate vaccines worldwide and 11 are licensed for public use in various countries. The speed with which the virus will be eliminated from the communities thus would depend not only on the presence of an efficient vaccine but also on the efforts to remove vaccine hesitancy, training of health workers and adequate vaccine coverage.

How to cite this article:

Athavale AV. The Covid-19 Vaccine. J Adv Res Med Sci Tech 2021; 8(1): 29-35.



Yadav S; Rawal G. The corona virus disease 2019 vaccine-A step to halt the devastation by the pandemic of SARS-CoV-2. IJIRM (IP Indian Journal of Immunology and Respiratory Medicine) 2020; 5(4): 196-197.

Shin MD, Shukla S, Chung YH et al. COVID-19 vaccine development and a potential nano material path forward. Nat Nanotechnol 2020; 15(8): 646-655.

Mehrotra DV, Janes HE, Fleming TR et al. Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials. Ann Intern Med 2021; 174(2): 221-228.

Graham BS. Rapid COVID-19 vaccine development. Science 2020; 368(6494): 945-946.

Hodgson SH, Mansatta K, Mallett G et al. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. The Lancet Infectious Diseases 2021; 21(2): e26-e35.

Bartsch SM, O’Shea KJ, Ferguson MC et al. Vaccine Efficacy Needed for a COVID-19 Corona virus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention. American Journal of Preventive Medicine 2020; 59(4): 493-503.

Vinod N. Stages in COVID-19 vaccine development: The Nemesis, the Hubris and the Elpis. Int J Clin Virol 2020; 4(1): 126-135.

Ella K, Mohan V. Coronav irus Vaccine: Light at the End of the Tunnel. Indian Pediatrics 2020; 57(5): 407-410.

Sharma O, Sultan AA, Ding H et al. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Front Immunol 2020; 11.

Rawat K, Kumari P, Saha L. COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. European Journal of Pharmacology 2021; 892: 173751.

Sauer K, Harris T. An Effective COVID-19 Vaccine Needs to Engage T Cells. Front Immunol 2020; 11.

Haque A, Pant AB. Efforts at COVID-19 Vaccine Development: Challenges and Successes. Vaccines 2020; 8(4): 739 (16 pages).

Arora NK, Das MK. COVID-19 vaccine development and the way forward. Indian J Public Health 2020; 64(6): s108-11.

Velavan TP, Pollard AJ, Kremsner PG. Herd immunity and vaccination of children for COVID-19. International Journal of Infectious Diseases 2020; 98: 14-15.

Lipsitch M, Dean NE. Understanding COVID-19 vaccine efficacy. Science 2020; 370(6518): 763-765.

Peiris M, Leung GM. What can we expect from firstgeneration COVID-19 vaccines? The Lancet 2020; 396(10261): 1467-9.

Haynes BF, Corey L, Fernandes P et al. Prospects for a safe COVID-19 vaccine. Sci Transl Med 2020; 12(568): eabe0948.

Kamidani S, Rostad CA, Anderson EJ. COVID-19 vaccine development: a pediatric perspective. Current Opinion in Pediatrics 2021; 33(1): 144-151.

Voysey M, Costa Clemens S, Madhi S. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials [Internet]. https:// 2021 [cited 22 February 2021].

Agnani M. Precautions and Contraindications for COVID - 19 vaccination. Ministry of Health and Family Welfare, Government of India, New Delhi; 2021.

George G. India’s first vaccine shots may be available from January 2021. [online] BioTecNika. Available at: [Accessed 23Feb 2021] 2021. COVID-19 Vaccine Rollout in India: State by State. [online] Available at: edu/IndiaVaccine[Accessed 22 February 2021]. 2021. COVID-19 vaccine tracker. [online] Available at: news-articles/2020/3/covid-19-vaccine-tracker [Accessed 22 February 2021] 2021. Draft landscape and tracker of COVID-19 candidate vaccines. [online] 2021. Available at: https://[Accessed 22 February 2021].

Al Awaidy ST, Khamis F. Preparing the Community for a Vaccine Against COVID-19. Oman Med J 2020; 35(6): e193.

Lazarus JV, Ratzan SC, Palayew A et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med 2021; 27(2): 225-228.

Jones D, Helmreich S. A history of herd immunity. The Lancet 2020; 396(10254): 810-811. 28. Giubilini A, Savulescu J, Wilkinson D. COVID-19 vaccine: vaccinate the young to protect the old?. Journal of Law and the Biosciences 2020; 7(1).

Giubilini A, Savulescu J, Wilkinson D. COVID-19 vaccine: vaccinate the young to protect the old?. Journal of Law and the Biosciences 2020; 7(1).